- Home
- RGC vs MDWD Comparison
RGC vs MDWD Comparison
Compare RGC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- MDWD
- Stock Information
- Founded
- RGC 2014
- MDWD 2000
- Country
- RGC Hong Kong
- MDWD Israel
- Employees
- RGC N/A
- MDWD N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- RGC Health Care
- MDWD Health Care
- Exchange
- RGC Nasdaq
- MDWD Nasdaq
- Market Cap
- RGC 171.1M
- MDWD 179.1M
- IPO Year
- RGC 2021
- MDWD 2014
- Fundamental
- Price
- RGC $6.12
- MDWD $17.11
- Analyst Decision
- RGC
- MDWD Strong Buy
- Analyst Count
- RGC 0
- MDWD 1
- Target Price
- RGC N/A
- MDWD $28.00
- AVG Volume (30 Days)
- RGC 35.0K
- MDWD 60.3K
- Earning Date
- RGC 10-25-2024
- MDWD 08-14-2024
- Dividend Yield
- RGC N/A
- MDWD N/A
- EPS Growth
- RGC N/A
- MDWD N/A
- EPS
- RGC N/A
- MDWD N/A
- Revenue
- RGC N/A
- MDWD $20,141,000.00
- Revenue This Year
- RGC N/A
- MDWD $30.16
- Revenue Next Year
- RGC N/A
- MDWD $18.44
- P/E Ratio
- RGC N/A
- MDWD N/A
- Revenue Growth
- RGC N/A
- MDWD N/A
- 52 Week Low
- RGC $3.03
- MDWD $7.45
- 52 Week High
- RGC $32.44
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- RGC 41.60
- MDWD 44.34
- Support Level
- RGC $5.52
- MDWD $16.25
- Resistance Level
- RGC $6.57
- MDWD $17.48
- Average True Range (ATR)
- RGC 0.82
- MDWD 1.02
- MACD
- RGC -0.26
- MDWD -0.19
- Stochastic Oscillator
- RGC 16.09
- MDWD 20.00
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.